{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T20:58:33Z","timestamp":1773694713925,"version":"3.50.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,11,20]],"date-time":"2012-11-20T00:00:00Z","timestamp":1353369600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tumor Biol."],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1007\/s13277-012-0583-0","type":"journal-article","created":{"date-parts":[[2012,11,19]],"date-time":"2012-11-19T04:45:05Z","timestamp":1353300305000},"page":"571-576","source":"Crossref","is-referenced-by-count":82,"title":["The role of novel biomarker HE4 in endometrial cancer: a case control prospective study"],"prefix":"10.1007","volume":"34","author":[{"given":"Roberto","family":"Angioli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Plotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stella","family":"Capriglione","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Montera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrizio","family":"Damiani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Ricciardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessia","family":"Aloisi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Luvero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ester Valentina","family":"Caf\u00e0","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nella","family":"Dugo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michela","family":"Angelucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierluigi","family":"Benedetti-Panici","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,11,20]]},"reference":[{"issue":"5","key":"583_CR1","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1158\/1055-9965.EPI-04-0871","volume":"14","author":"F Bray","year":"2005","unstructured":"Bray F, Dos Santos Silva I, Moller H, Weiderpass E. Endometrial cancer incidence trends in Europe: underlying determinants and prospects for prevention. Cancer Epidemiol Biomarkers Prev. 2005;14(5):1132\u201342.","journal-title":"Cancer Epidemiol Biomarkers Prev."},{"issue":"4","key":"583_CR2","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3322\/caac.20006","volume":"59","author":"A Jemal","year":"2009","unstructured":"Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59(4):225\u201349.","journal-title":"CA Cancer J Clin."},{"issue":"9213","key":"583_CR3","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/S0140-6736(00)02139-5","volume":"355","author":"CL Creutzberg","year":"2000","unstructured":"Creutzberg CL, van Putten WL, Koper PC, Lybeert ML, Jobsen JJ, W\u00e1rl\u00e1m-Rodenhuis CC, et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet. 2000;355(9213):1404\u201311.","journal-title":"Lancet"},{"issue":"2","key":"583_CR4","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s00404-006-0138-y","volume":"274","author":"A Papanikolaou","year":"2006","unstructured":"Papanikolaou A, Kalogiannidis I, Goutzioulis M, Misailidou D, Makedos A, Vergote I, et al. Pelvic lymphadenectomy as alternative to postoperative radiotherapy in high risk early stage endometrial cancer. Arch Gynecol Obstet. 2006;274(2):91\u20136.","journal-title":"Arch Gynecol Obstet."},{"issue":"5","key":"583_CR5","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1002\/uog.1704","volume":"24","author":"R Smith-Bindman","year":"2004","unstructured":"Smith-Bindman R, Weiss E, Feldstein V. How thick is too thick? When endometrial thickness should prompt biopsy in postmenopausal women without vaginal bleeding. Ultrasound Obstet Gynecol. 2004;24(5):558\u201365.","journal-title":"Ultrasound Obstet Gynecol."},{"issue":"2","key":"583_CR6","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/0090-8258(88)90032-7","volume":"30","author":"G Scambia","year":"1988","unstructured":"Scambia G, Benedetti Panici P, Baiocchi G, Perrone L, Greggi S, Mancuso S. CA 15\u20133 as a tumor marker in gynecological malignancies. Gynecol Oncol. 1988;30(2):265\u201373.","journal-title":"Gynecol Oncol."},{"issue":"2","key":"583_CR7","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ygyno.2008.04.002","volume":"110","author":"RG Moore","year":"2008","unstructured":"Moore RG, Brown AK, Miller MC, Badgwell D, Lu Z, Allard WJ, et al. Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus. Gynecol Oncol. 2008;110(2):196\u2013201.","journal-title":"Gynecol Oncol."},{"key":"583_CR8","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1038\/bjc.2011.109","volume":"104","author":"E Bignotti","year":"2011","unstructured":"Bignotti E, Ragnoli M, Zanotti L, Calza S, Falchetti M, Lonardi S, et al. Diagnostic and prognostic impact of serum HE4 detection in endometrial carcinoma patiens. Br J Cancer. 2011;104:1418\u201325.","journal-title":"Br J Cancer."},{"key":"583_CR9","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1371\/journal.pmed.0050023","volume":"5","author":"R Drapkin","year":"2008","unstructured":"Drapkin R, von Horsten HH, Lin Y, et al. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res. Kobel M, Kalloger SE, Boyd N, et al. Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med. 2008;5:e23.","journal-title":"PLoS Med."},{"key":"583_CR10","doi-asserted-by":"crossref","unstructured":"Plotti F, Capriglione S, Terranova C, Montera R, Aloisi A, Damiani P, Muzii L, Scaletta G, Benedetti-Panici P, Angioli R. Does HE4 have a role as biomarker in the recurrence of ovarian cancer? Tumour Biol. 2012 Aug 9.","DOI":"10.1007\/s13277-012-0471-7"},{"issue":"3","key":"583_CR11","first-page":"321","volume":"54","author":"IM Duk","year":"1994","unstructured":"Duk IM. CA125: a useful marker in endometrial carcinoma. Am J Obstet Gynaecol Oncol. 1994;54(3):321\u20136.","journal-title":"Am J Obstet Gynaecol Oncol"},{"key":"583_CR12","first-page":"272","volume":"5","author":"A Gadducci","year":"1992","unstructured":"Gadducci A, Ferdeghini M, Caenaro GF, Prontera C, Malagnino G, Annichiarico C, et al. Immunoacid protein (IAP) as marker for cervical and endometrial carcinoma: alone and in comparison with CA 125 and SCC. Cancer J. 1992;5:272\u20138.","journal-title":"Cancer J."},{"issue":"4","key":"583_CR13","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1002\/1097-0142(1984)54:4<652::AID-CNCR2820540411>3.0.CO;2-C","volume":"54","author":"M Sawada","year":"1984","unstructured":"Sawada M, Okudaira Y, Matsui Y, Shimizu Y. Immunosuppressive acidic protein in patients with gynecologic cancer. Cancer. 1984;54(4):652\u20136.","journal-title":"Cancer"},{"issue":"3","key":"583_CR14","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1006\/gyno.1994.1217","volume":"54","author":"N Takeshima","year":"1994","unstructured":"Takeshima N, Shimizu Y, Umezawa S, Hirai Y, Chen JT, Fujimoto I, et al. Combined assay of serum levels of CA125 and CA19-9 in endometrial carcinoma. Gynecol Oncol. 1994;54(3):321\u20136.","journal-title":"Gynecol Oncol."},{"issue":"3","key":"583_CR15","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1006\/gyno.1994.1213","volume":"54","author":"G Scambia","year":"1994","unstructured":"Scambia G, Gadducci A, Panici PB, Foti E, Ferdeghini M, Ferrandina G, et al. Combined use of CA 125 and CA 15\u20133 in patients with endometrial carcinoma. Gynecol Oncol. 1994;54(3):292\u20137.","journal-title":"Gynecol Oncol."},{"issue":"4","key":"583_CR16","first-page":"315","volume":"20","author":"PL Cherchi","year":"1999","unstructured":"Cherchi PL, Dessole S, Ruiu GA, Ambrosini G, Farina M, Capobianco G, et al. The value of serum CA 125 and association CA 125\/CA 19\u20139 in endometrial carcinoma. Eur J Gynaecol Oncol. 1999;20(4):315\u20137.","journal-title":"Eur J Gynaecol Oncol."},{"issue":"12","key":"583_CR17","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1136\/jcp.49.12.967","volume":"49","author":"H Hareyama","year":"1996","unstructured":"Hareyama H, Sakuragi N, Makinoda S, Fujimoto S. Serum and tissue measurements of CA72-4 in patients with endometrial carcinoma. J Clin Pathol. 1996;49(12):967\u201370.","journal-title":"J Clin Pathol."},{"issue":"4","key":"583_CR18","first-page":"283","volume":"11","author":"A Gadducci","year":"1990","unstructured":"Gadducci A, Ferdeghini M, Prontera C, Giordano P, Cristofani R, Bianchi R, et al. A comparison of pretreatment serum levels of four tumor markers in patients with endometrial and cervical carcinoma. Eur J Gynaecol Oncol. 1990;11(4):283\u20138.","journal-title":"Eur J Gynaecol Oncol."},{"issue":"1","key":"583_CR19","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/0002-9378(95)90178-7","volume":"173","author":"A Hakala","year":"1995","unstructured":"Hakala A, Kacinski BM, Stanley ER, Kohorn EI, Puistola U, Risteli J, et al. Macrophage colony-stimulating factor 1, a clinically useful tumor marker in endometrial adenocarcinoma: comparison with CA 125 and the aminoterminal propeptide of type III procollagen. Am J Obstet Gynecol. 1995;173(1):112\u20139.","journal-title":"Am J Obstet Gynecol."},{"issue":"6B","key":"583_CR20","first-page":"4635","volume":"18","author":"C Peters-Engl","year":"1998","unstructured":"Peters-Engl C, Buxbaum P, Ogris E, Sevelda P, Medl M. TATI (tumor associated trypsin inhibitor) and cancer antigen 125 (CA 125) in patients with early-stage endometrial cancer. Anticancer Res. 1998;18(6B):4635\u20139.","journal-title":"Anticancer Res."},{"issue":"4","key":"583_CR21","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1046\/j.1525-1438.2002.01007.x","volume":"12","author":"S Ginath","year":"2002","unstructured":"Ginath S, Menczer J, Fintsi Y, Ben-Shem E, Glezerman M, Avinoach I. Tissue and serum CA125 expression in endometrial cancer. Int J Gynecol Cancer. 2002;12(4):372\u20135.","journal-title":"Int J Gynecol Cancer."},{"issue":"3","key":"583_CR22","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S0029-7844(97)00286-X","volume":"90","author":"AK Sood","year":"1997","unstructured":"Sood AK, Buller RE, Burger RA, Dawson JD, Sorosky JI, Berman M. Value of preoperative CA 125 level in the management of uterine cancer and prediction of clinical outcome. Obstet Gynecol. 1997;90(3):441\u20137.","journal-title":"Obstet Gynecol."},{"issue":"1","key":"583_CR23","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1006\/gyno.2002.6664","volume":"86","author":"CH Hsieh","year":"2002","unstructured":"Hsieh CH, ChangChien CC, Lin H, Huang EY, Huang CC, Lan KC, et al. Can a preoperative CA 125 level be a criterion for full pelvic lymphadenectomy in surgical staging of endometrial cancer? Gynecol Oncol. 2002;86(1):28\u201333.","journal-title":"Gynecol Oncol."},{"issue":"2","key":"583_CR24","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1006\/gyno.1997.4620","volume":"65","author":"EP Beck","year":"1997","unstructured":"Beck EP, Wagner M, Anselmino L, Xu F, Bast Jr RC, Jaeger W. Is OVX1 a suitable marker for endometrial cancer? Gynecol Oncol. 1997;65(2):291\u20136.","journal-title":"Gynecol Oncol."},{"issue":"3","key":"583_CR25","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1006\/gyno.1996.0331","volume":"63","author":"PM Carpenter","year":"1996","unstructured":"Carpenter PM, Gamboa GP, Dorion GE, Ramsinghani NS, A\u00efssi AM, Manetta A. Radiation-induced CA 125 production by mesothelial cells. Gynecol Oncol. 1996;63(3):328\u201332.","journal-title":"Gynecol Oncol."},{"issue":"7","key":"583_CR26","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1097\/IGC.0b013e3182229ad8","volume":"21","author":"RG Moore","year":"2011","unstructured":"Moore RG, Miller CM, Brown AK, Robison K, Steinhoff M, Lambert-Messerlian G. Utility of tumor marker HE4 to predict depth of myometrial invasion in endometrioid adenocarcinoma of the uterus. Int J Gynecol Cancer. 2011;21(7):1185\u201390.","journal-title":"Int J Gynecol Cancer."},{"issue":"2","key":"583_CR27","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.ygyno.2011.10.025","volume":"124","author":"E Kalogera","year":"2012","unstructured":"Kalogera E, Scholler N, Powless C, Weaver A, Drapkin R, Li J, et al. Correlation of serum HE4 with tumor size and myometrial invasion in endometrial cancer. Gynecol Oncol. 2012;124(2):270\u20135. Epub 2011 Oct 28.","journal-title":"Gynecol Oncol."},{"key":"583_CR28","first-page":"4779","volume":"30","author":"M Kamei","year":"2010","unstructured":"Kamei M, Yamashita S, Tokuishi K, Hashioto T, Moroga T, Suehiro S, et al. HE4 expression can be associated with lymph node metastases and disease-free survival in breast cancer. Anticancer Res. 2010;30:4779\u201383.","journal-title":"Anticancer Res."}],"container-title":["Tumor Biology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13277-012-0583-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13277-012-0583-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13277-012-0583-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T03:37:24Z","timestamp":1745206644000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13277-012-0583-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11,20]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["583"],"URL":"https:\/\/doi.org\/10.1007\/s13277-012-0583-0","relation":{},"ISSN":["1010-4283","1423-0380"],"issn-type":[{"value":"1010-4283","type":"print"},{"value":"1423-0380","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,11,20]]}}}